查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1970927

用於血液檢測的運動醫學生物標記市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、地區和競爭格局分類，2021-2031年

Blood-based Biomarker For Sports Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球運動醫學血液生物標記市場預計將從 2025 年的 8.1312 億美元成長到 2031 年的 11.6391 億美元，複合年成長率為 6.16%。

這些生物標記分析血液中的生物指標，作為專業的診斷工具，用於測量生理壓力、評估傷害嚴重程度並指南運動員的復健策略。市場成長的關鍵促進因素是運動相關損傷發生率的上升以及對客觀數據以縮短復原時間的需求日益成長。這些因素要求在標準身體檢查之外，需要更精確的體內監測能力，這反映出產業有長期而非暫時的需求。例如，根據美國國家安全委員會的報告，到2024年，約有440萬人將因運動和休閒器材相關損傷而需要急診治療。這凸顯了迫切需要有效的診斷方法來支持安全重返賽場的決策。

市場概覽
預測期 2027-2031
市場規模：2025年 8.1312億美元
市場規模：2031年 1,163,910,000 美元
複合年成長率：2026-2031年 6.16%
成長最快的細分市場 尿素
最大的市場 北美洲

然而，市場擴張的一大障礙是頻繁血液檢測和分析的高成本。小規模體育組織和業餘聯賽往往缺乏資金來承擔定期生物標記篩檢所需的物流和檢測費用。這種經濟限制使得這些診斷方案的應用範圍主要局限於精英職業隊，從而為更廣泛的運動員群體設置了很高的准入門檻。

市場促進因素

就地檢驗技術的進步有效地降低了市場准入門檻，將診斷能力從遠端檢查室直接轉移到了體育場邊。這種轉變使得醫護人員能夠在撞擊後立即量化腦損傷指標，例如泛素C端水解酵素L1 (UCH-L1) 和膠質纖維酸性蛋白 (GFAP)，無需等待數小時才能獲得結果。例如，2025年5月，雅培公司宣佈在其所有MotoAmerica賽事中部署手持式i-STAT TBI檢測儀，該檢測儀可在15分鐘內提供檢查室級別的精確結果，以促進對腦震蕩的即時評估。隨著各聯盟加強安全措施，這種精準的診斷變得越來越重要。美國國家美式足球聯盟 (NFL) 報告稱，2024年賽季腦震盪發生率下降了17%，凸顯了對傷病管理策略的嚴格重視。

此外，將人工智慧融入生物標記分析正在加速市場成長，因為它能夠準確解讀複雜的生物數據，並為每位運動員提供個人化護理。人工智慧演算法可以長期監測血液指標，檢測細微的生理異常，從而製定客製化的恢復通訊協定，最大限度地提高運動員的出場率。這種潛力正在推動該領域的大規模投資；例如，愛爾蘭企業局 (Enterprise Ireland) 在 2025 年 12 月報告稱，Orreco 已籌集 400 萬美元，用於擴展其人工智慧驅動的運動表現智慧平台。該平台將生物標記數據與外部負荷指標關聯起來，以降低受傷風險，使團隊能夠就運動員重返賽場做出客觀、數據驅動的決策。

市場挑戰

頻繁的血液檢測和分析成本高昂，構成了限制市場擴充性的重大經濟障礙。與只需一次性硬體投入的非侵入性監測工具不同，基於血液的生物標記分析涉及持續的支出，例如採血專家的工資、低溫運輸物流以及專業檢查室分析的費用。這些營運需求導致每次檢測的高成本，對於絕大多數體育組織而言，在經濟上難以負擔。因此，這些診斷方案的應用主要局限於擁有雄厚醫療預算的精英職業球隊，難以滲透到預算緊張的業餘和大學運動領域。

這種營運上的差異也反映在全球侵入性檢測方法的普及率上。根據世界反興奮劑機構（WADA）統計，2024年全球經認證的實驗室僅分析了31,003份血液和乾血斑檢體，僅佔運動員生物檢體總數的一小部分。即使在國際體育賽事監管最嚴格的級別，如此有限的檢體量也凸顯了血液檢測在後勤和經濟方面固有的障礙。因此，血液檢測市場難以突破頂級競技運動的限制，而常規內部監測所需的投資對於普通市場而言仍然難以承受。

市場趨勢

面向消費者的運動員血液檢測服務的興起，正從根本上改變著市場的可及性，使業餘和半職業運動員也能享受到專業級的診斷服務。以往只有擁有專業醫療團隊的精英機構才能提供的全面血液分析，如今透過繞過傳統醫療安全隔離網閘的訂閱模式，健身愛好者也能直接獲得這項服務。這一趨勢推動了檢測量的增加，生物標記分析被整合到標準的健身會員服務中，使用戶能夠自主追蹤自身的生理基準。例如，2024年5月，InsideTracker與FITNESS SF合作，將血液生物標記分析直接整合到會員計畫中，為超過35,000名客戶提供每年兩次的血液檢測，以最佳化訓練和恢復。

此外，微創毛細血管採血技術的開發消除了傳統靜脈穿刺帶來的許多後勤障礙，從而能夠進行高頻監測，這對於長期追蹤運動員的健康狀況至關重要。與需要專業採血技術人員的侵入性針刺不同，這種新型微量採血裝置使運動員即使在偏遠地區也能準確地從上臂或指尖自行採集樣本。這項創新對於推廣運動表現提升和反興奮劑項目至關重要，因為在這些項目中，後勤便利性和運動員的舒適度是重中之重。為了說明這項技術的廣泛應用，Tasso公司於2024年7月宣布，其毛細血管採血技術將在包括2024年巴黎奧運在內的重大國際賽事中得到應用，這將有助於簡化檢體採集流程，並提升運動員的體驗。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：運動醫學血液檢測生物標記的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（CK、肌紅蛋白、乳酸、白血球計數、尿素、CRP、脂質和蛋白質氫過氧化物、IL-6、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美運動醫學血液檢測生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲運動醫學血液檢測生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區運動醫學血液檢測生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲運動醫學血液檢測生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲運動醫學血液檢測生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球運動醫學血液檢測生物標記市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories
  • BIOMeRIEUX
  • F. Hoffmann-La Roche Ltd.
  • ARUP Laboratories Inc.
  • Siemens Healthineers AG
  • RayBiotech, Inc
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc
  • Beckman Coulter, Inc.
  • Randox Laboratories Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27717

The Global Blood-based Biomarker For Sports Medicine Market is projected to increase from USD 813.12 Million in 2025 to USD 1163.91 Million by 2031, registering a CAGR of 6.16%. These biomarkers function as specialized diagnostic instruments that examine biological indicators within the blood to measure physiological stress, assess injury severity, and guide recovery strategies for athletes. The primary factors driving market growth are the rising incidence of sports-related injuries and the increasing demand for objective data to shorten recovery timelines. These drivers necessitate accurate internal monitoring capabilities that surpass standard physical evaluations and represent permanent industry needs rather than temporary shifts. For example, the National Safety Council reported that in 2024, approximately 4.4 million individuals were treated in emergency departments for injuries involving sports and recreational equipment, underscoring the urgent need for effective diagnostics to support safe return-to-play decisions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 813.12 Million
Market Size 2031USD 1163.91 Million
CAGR 2026-20316.16%
Fastest Growing SegmentUrea
Largest MarketNorth America

However, a significant obstacle impeding market expansion is the high cost associated with implementing frequent blood profiling and analysis. Smaller sports organizations and amateur leagues often lack the financial means to cover the logistical and laboratory expenses necessary for routine biomarker screening. This economic limitation restricts the scalability of these diagnostic solutions largely to elite professional franchises, creating a substantial barrier to entry for the broader athletic population.

Market Driver

Technological advancements in point-of-care testing are effectively lowering entry barriers in the market by relocating diagnostic capabilities from remote laboratories directly to the athletic sideline. This transition allows medical staff to instantly quantify brain injury indicators, such as ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), immediately following a collision instead of waiting hours for results. For instance, in May 2025, Abbott announced that its handheld i-STAT TBI test, which provides lab-quality results within 15 minutes, was deployed at all MotoAmerica races to facilitate real-time concussion assessment. Such precise diagnostics are becoming increasingly vital as leagues strengthen safety protocols; the NFL reported a 17% decrease in concussions during the 2024 season, highlighting a rigorous focus on injury management strategies.

Furthermore, the integration of artificial intelligence into biomarker analysis is accelerating market growth by enabling the precise interpretation of complex biological data for personalized athlete care. AI algorithms can examine longitudinal blood profiles to detect subtle physiological deviations, allowing for customized recovery protocols that optimize player availability. This potential has triggered significant investment in the sector; for example, Enterprise Ireland reported in December 2025 that Orreco raised $4 million to scale its AI-powered performance intelligence platform. This platform correlates biomarker data with external load metrics to reduce injury risks, collectively empowering teams to make objective, data-driven decisions regarding an athlete's return to play.

Market Challenge

The prohibitive cost associated with establishing frequent blood profiling and analysis creates a severe economic barrier that limits the scalability of the market. Unlike non-invasive monitoring tools that involve a one-time hardware expense, blood-based biomarker analysis requires recurring expenditures for phlebotomy professionals, cold-chain logistics, and specialized laboratory assays. These operational demands result in a high cost-per-test structure that is financially unsustainable for the majority of athletic organizations. Consequently, the adoption of these diagnostic solutions is largely restricted to elite professional franchises with substantial medical budgets, preventing penetration into the wider amateur and collegiate sports sectors where financial resources are strictly allocated.

This operational disparity is evident in the global utilization rates of invasive testing methods. According to the World Anti-Doping Agency, accredited laboratories analyzed 31,003 blood and dried blood spot samples worldwide in 2024, a figure representing only a small fraction of the total biological samples collected from athletes. This limited volume, even within the most highly regulated tier of international sports, underscores the logistical and financial friction inherent in blood-based diagnostics. As a result, the market struggles to expand beyond the top tier of competitive sports, as the requisite investment for routine internal monitoring remains out of reach for the mass market.

Market Trends

The rise of Direct-to-Consumer (DTC) athlete blood testing services is fundamentally reshaping market accessibility by democratizing professional-grade diagnostics for the amateur and semi-professional sectors. Previously the exclusive domain of elite franchises with dedicated medical staff, comprehensive blood profiling is now directly available to fitness enthusiasts through subscription-based models that bypass traditional clinical gatekeepers. This trend drives volume growth by integrating biomarker analysis into standard fitness memberships, allowing individuals to track physiological baselines independently. For example, in May 2024, InsideTracker partnered with FITNESS SF to integrate its blood biomarker analytics directly into membership tiers, providing over 35,000 clients with biannual blood testing to optimize training and recovery.

Additionally, the development of minimally invasive capillary blood sampling technologies is removing the logistical friction of traditional venipuncture, thereby enabling the high-frequency monitoring essential for longitudinal athlete tracking. Unlike invasive needle draws that require phlebotomy professionals, novel microsampling devices allow athletes to self-collect precise samples from the upper arm or fingertip in remote settings. This innovation is critical for scaling performance and anti-doping programs where logistical ease and athlete comfort are paramount. Demonstrating this widespread acceptance, Tasso announced in July 2024 that its capillary blood collection technology was deployed at major international events, including the Paris 2024 Olympic Games, to streamline sample collection processes and enhance the athlete experience.

Key Market Players

  • Abbott Laboratories
  • BIOMeRIEUX
  • F. Hoffmann-La Roche Ltd.
  • ARUP Laboratories Inc.
  • Siemens Healthineers AG
  • RayBiotech, Inc
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc
  • Beckman Coulter, Inc.
  • Randox Laboratories Ltd.

Report Scope

In this report, the Global Blood-based Biomarker For Sports Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Blood-based Biomarker For Sports Medicine Market, By Type

  • CK
  • Myoglobin
  • Lactate
  • WBC
  • Urea
  • CRP
  • Lipid and Protein Hydroperoxides
  • IL-6
  • Others

Blood-based Biomarker For Sports Medicine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood-based Biomarker For Sports Medicine Market.

Available Customizations:

Global Blood-based Biomarker For Sports Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Blood-based Biomarker For Sports Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (CK, Myoglobin, Lactate, WBC, Urea, CRP, Lipid and Protein Hydroperoxides, IL-6, Others)
    • 5.2.2. By Region
    • 5.2.3. By Company (2025)
  • 5.3. Market Map

6. North America Blood-based Biomarker For Sports Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Blood-based Biomarker For Sports Medicine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
    • 6.3.2. Canada Blood-based Biomarker For Sports Medicine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
    • 6.3.3. Mexico Blood-based Biomarker For Sports Medicine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type

7. Europe Blood-based Biomarker For Sports Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Blood-based Biomarker For Sports Medicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
    • 7.3.2. France Blood-based Biomarker For Sports Medicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
    • 7.3.3. United Kingdom Blood-based Biomarker For Sports Medicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
    • 7.3.4. Italy Blood-based Biomarker For Sports Medicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
    • 7.3.5. Spain Blood-based Biomarker For Sports Medicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type

8. Asia Pacific Blood-based Biomarker For Sports Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Blood-based Biomarker For Sports Medicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
    • 8.3.2. India Blood-based Biomarker For Sports Medicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
    • 8.3.3. Japan Blood-based Biomarker For Sports Medicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
    • 8.3.4. South Korea Blood-based Biomarker For Sports Medicine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
    • 8.3.5. Australia Blood-based Biomarker For Sports Medicine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type

9. Middle East & Africa Blood-based Biomarker For Sports Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Blood-based Biomarker For Sports Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
    • 9.3.2. UAE Blood-based Biomarker For Sports Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
    • 9.3.3. South Africa Blood-based Biomarker For Sports Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type

10. South America Blood-based Biomarker For Sports Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Blood-based Biomarker For Sports Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
    • 10.3.2. Colombia Blood-based Biomarker For Sports Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
    • 10.3.3. Argentina Blood-based Biomarker For Sports Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Blood-based Biomarker For Sports Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. BIOMeRIEUX
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. ARUP Laboratories Inc.
  • 15.5. Siemens Healthineers AG
  • 15.6. RayBiotech, Inc
  • 15.7. Thermo Fisher Scientific, Inc.
  • 15.8. Bio-Rad Laboratories, Inc
  • 15.9. Beckman Coulter, Inc.
  • 15.10. Randox Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer